{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:13:04Z","timestamp":1775149984462,"version":"3.50.1"},"reference-count":33,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003448","name":"European Union and Greek National Funds","doi-asserted-by":"publisher","award":["T1EDK-01612"],"award-info":[{"award-number":["T1EDK-01612"]}],"id":[{"id":"10.13039\/501100003448","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Gemcitabine has been used to treat various solid cancers, including, since 1997, metastatic pancreatic cancer. Here, we developed an HPLC-UV method to determine serum gemcitabine levels and use it in pharmacokinetic studies. Materials and Methods: The analysis was performed after a single protein precipitation step on a reversed-phase column, isocratically eluted with sodium phosphate buffer and methanol. For the pharmacokinetic study, NOD\/SCID mice received a single dose of gemcitabine at 100 mg\/kg by either subcutaneous (SC) or intraperitoneal (IP) administration. Blood samples were collected at 5, 15, and 30 min and 1, 2, 4, and 6 h after the administration of gemcitabine for further analysis. Results: The duration of the analysis was ~12.5 min. The calibration curve was linear (r2 = 0.999) over the range of 1\u2013400 \u03bcM. The mean recovery of GEM was 96.53% and the limit of detection was 0.166 \u03bc\u039c. T1\/2, Tmax, Cmax, AUC0\u2013t, and clearance were 64.49 min, 5.00 min, 264.88 \u03bcmol\/L, 9351.95 \u03bcmol\/L*min, and 0.0103(mg)\/(\u03bcmol\/L)\/min, respectively, for the SC administration. The corresponding values for the IP administration were 59.34 min, 5.00 min, 300.73 \u03bcmol\/L, 8981.35 \u03bcmol\/L*min and 0.0108(mg)\/(\u03bcmol\/L)\/min (not statistically different from the SC administration). Conclusions: A simple, valid, sensitive, and inexpensive method for the measurement of gemcitabine in serum has been developed. This method may be useful for monitoring gemcitabine levels in cancer patients as part of therapeutic drug monitoring.<\/jats:p>","DOI":"10.3390\/medicina60060864","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T10:14:07Z","timestamp":1716804847000},"page":"864","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Development and Validation of a Simple and Reliable HPLC-UV Method for Determining Gemcitabine Levels: Application in Pharmacokinetic Analysis"],"prefix":"10.3390","volume":"60","author":[{"given":"Konstantinos","family":"Lafazanis","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Begas","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7058-5257","authenticated-orcid":false,"given":"Irida","family":"Papapostolou","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9358-0769","authenticated-orcid":false,"given":"Hermis","family":"Iatrou","sequence":"additional","affiliation":[{"name":"Industrial Chemistry Laboratory, Department of Chemistry, National and Kapodistrian University of Athens, 10676 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikos","family":"Sakellaridis","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0866-1930","authenticated-orcid":false,"given":"Dimitrios","family":"Vlassopoulos","sequence":"additional","affiliation":[{"name":"FORTH, Institute for Electronic Structure and Laser, 71110 Heraklion, Greece"},{"name":"Department of Materials Science and Technology, University of Crete, 71003 Heraklion, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Dimas","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, University of Thessaly, 41500 Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","volume":"17","author":"Mini","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"104967","DOI":"10.1016\/j.antiviral.2020.104967","article-title":"Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation","volume":"184","author":"Li","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jchromb.2006.03.023","article-title":"High-performance liquid chromatographic method for the determination of gemcitabine and 2\u2032,2\u2032-difluorodeoxyuridine in plasma and tissue culture media","volume":"835","author":"Kirstein","year":"2006","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_5","unstructured":"Committee for Medicinal Products for Human Use, and European Medicines Agency (EMA) (2023, October 23). EMEA\/CHMP\/EWP\/192217\/2009 Rev. 1 Corr. 2**. 2011, Chapters 4.1.3 and 4.1.9. in Guideline on Bioanalytical Method Validation. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Snyder, L.R., Kirkland, J.J., and Glajch, L.J. (1997). Practical HPLC Method Development, John Wiley & Sons INC.. [2nd ed.].","DOI":"10.1002\/9781118592014"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jssc.200600534","article-title":"Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC","volume":"12","author":"Lanz","year":"2007","journal-title":"J. Sep. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Programs Biomed."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jprot.2018.01.012","article-title":"Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: Emerging allies in the war on a devastating cancer?","volume":"188","author":"Sereti","year":"2018","journal-title":"J. Proteom."},{"key":"ref_10","first-page":"6823","article-title":"Pharmacologically directed design of the dose rate and schedule of 2\u2032,2\u2032-difluorodeoxycytidine (gemcitabine) administration in leukemia","volume":"50","author":"Grunewald","year":"1990","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/BF00685109","article-title":"Saturation of 2\u2032,2\u2032-difluorodeoxycytidine 5\u2032-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine","volume":"27","author":"Grunewald","year":"1991","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1200\/JCO.1992.10.3.406","article-title":"Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study","volume":"10","author":"Grunewald","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.bjc.6602673","article-title":"Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma","volume":"93","author":"Bengala","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","article-title":"A phase I clinical, plasma, and cellular pharmacology study of gemcitabine","volume":"9","author":"Abbruzzese","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2000.18.14.2780","article-title":"Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565","volume":"18","author":"Venook","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.21037\/jgo-22-624","article-title":"The efficacy and safety of gemcitabine-based combination therapy vs. gemcitabine alone for the treatment of advanced pancreatic cancer: A systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_17","first-page":"8812983","article-title":"A Severe Case of Drug-Induced Liver Injury after Gemcitabine Administration: A Highly Probable Causality Grading as Assessed by the Updated RUCAM Diagnostic Scoring System","volume":"2020","author":"Mascherona","year":"2020","journal-title":"Case Rep. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4103\/ijn.ijn_277_22","article-title":"Nephrotic Syndrome and Posterior Reversible Encephalopathy Syndrome as Clinical Presentations of Gemcitabine-Induced Thrombotic Micro-Angiopathy","volume":"34","author":"Jha","year":"2024","journal-title":"Indian J. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/FPC.0b013e32825ea6e3","article-title":"Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation","volume":"17","author":"Mercier","year":"2007","journal-title":"Pharmacogenet. Genom."},{"key":"ref_20","first-page":"1912","article-title":"Severe acute toxicity following gemcitabine administration: A report of four cases with cytidine deaminase polymorphisms evaluation","volume":"15","author":"Hryciuk","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0378-4347(94)00521-6","article-title":"Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection","volume":"665","author":"Freeman","year":"1995","journal-title":"J. Chromatogr. B Biomed. Appl."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1570-0232(02)00859-0","article-title":"Measurement of the anti-cancer agent gemcitabine in human plasma by high-performance liquid chromatography","volume":"785","author":"Keith","year":"2003","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1570-0232(03)00211-3","article-title":"Simultaneous determination of gemcitabine and its metabolite in human plasma by high-performance liquid chromatography","volume":"791","author":"Aksoy","year":"2003","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/00007691-200310000-00003","article-title":"An Expedient Assay for Determination of Gemcitabine and Its Metabolite in Human Plasma Using Isocratic Ion-Pair Reversed-Phase High-Performance Liquid Chromatography","volume":"25","author":"Wang","year":"2003","journal-title":"Ther. Drug Monit."},{"key":"ref_25","first-page":"1584","article-title":"Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector","volume":"25","author":"Lin","year":"2004","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_26","first-page":"59","article-title":"Development and validation of a rapid and simple reversed-phase HPLC method for the determination of gemcitabine in human plasma","volume":"6","author":"Vidal","year":"2014","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/chromsci\/bmaa020","article-title":"Determination of Gemcitabine in Plasma of Bladder Cancer Patients by Hydrophilic Interaction Chromatography with Ultraviolet Detection","volume":"58","author":"Wang","year":"2020","journal-title":"J. Chromatogr. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jchromb.2018.03.025","article-title":"Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2\u2032,2\u2032-difluorodeoxyuridine in rat plasma by UFLC-MS\/MS","volume":"1084","author":"Sun","year":"2018","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/FTD.0000000000000402","article-title":"A rapid homogeneous immunoassay to quantify gemcitabine in plasma for therapeutic drug monitoring (TDM)","volume":"39","author":"Kozo","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1080\/01496395.2023.2201392","article-title":"Development of a magnetic solid phase extraction method for gemcitabine from rat plasma by using magnetic graphene oxide calix[6]arene composite and its application to pharmacokinetics","volume":"58","author":"Palakeeti","year":"2023","journal-title":"Sep. Sci. Technol."},{"key":"ref_31","unstructured":"Meyer, V.R. (1994). Practical High-Performance Liquid Chromatography, John Wiley & Sons Ltd."},{"key":"ref_32","first-page":"600","article-title":"Administration of substances to laboratory animals: Routes of administration and factors to consider","volume":"50","author":"Turner","year":"2011","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"ref_33","first-page":"461","article-title":"Subcutaneous administration of biotherapeutics: Current experience in animal models","volume":"12","author":"McDonald","year":"2010","journal-title":"Curr. Opin. Mol. Ther."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/6\/864\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:48:50Z","timestamp":1760107730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/6\/864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["medicina60060864"],"URL":"https:\/\/doi.org\/10.3390\/medicina60060864","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,25]]}}}